Takeda to buy NDI-034858 from Nimbus Therapeutics in deal worth up to $6bn
To be renamed TAK-279 after the completion of the deal, NDI-034858 is being studied for the treatment of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Dec 22
To be renamed TAK-279 after the completion of the deal, NDI-034858 is being studied for the treatment of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Dec 22
The partnership combines GSK’s expertise in human genetics and genomics with Wave’s proprietary discovery and drug development oligonucleotide…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Dec 22
Horizon Therapeutics is a biotechnology company focused on discovering, developing, and marketing medicines that for rare, autoimmune, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
12 Dec 22
The collaboration will leverage Kite’s experience in cell therapy manufacturing to co-develop and co-commercialise Arcellx’s lead candidate CART-ddBCMA,…
09 Dec 22
The European Commission (EC) approved Qdenga (TAK-003) for use in individuals aged four years and above, administered subcutaneously…
09 Dec 22
Based on platform, the point-of-care and rapid diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks,…
08 Dec 22
Pfizer has received the FDA’s Prescription Drug User Fee Act (PDUFA) goal date of May 2023, for a…
07 Dec 22
This sparked the idea of using solely local capacities and products for humanitarian aid, as a result of…
NutraceuticalsProtein and Peptide Synthesis and Manufacturing
07 Dec 22
"We're so proud to welcome these newly certified partners into the Fairtrade community. Each of these brands showcase…
Brand Protection and Anti-counterfeitingMaintenance Management Systems
07 Dec 22
The two companies will jointly discover and develop a novel papain-like protease (PLpro) inhibitor oral antiviral candidate against…